CN113876640B - Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product - Google Patents
Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product Download PDFInfo
- Publication number
- CN113876640B CN113876640B CN202111356423.3A CN202111356423A CN113876640B CN 113876640 B CN113876640 B CN 113876640B CN 202111356423 A CN202111356423 A CN 202111356423A CN 113876640 B CN113876640 B CN 113876640B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- seaweed
- glycation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 241001474374 Blennius Species 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 30
- 241000628997 Flos Species 0.000 claims abstract description 20
- 229940075599 ascophyllum nodosum extract Drugs 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 239000006071 cream Substances 0.000 claims abstract description 9
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 20
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 241000594394 Hedyotis Species 0.000 claims 2
- 241001114003 Seira Species 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 230000013595 glycosylation Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 238000010256 biochemical assay Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 11
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000756137 Hemerocallis Species 0.000 description 5
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008406 cosmetic ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000007358 Magnolia biondii Species 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000698291 Rugosa Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a seaweed source composition, a preparation method thereof and application thereof in preparing anti-saccharification cosmetic products. The invention discloses a preparation method of a Chinese medicinal composition, which comprises the following steps of (by weight percent) 40-60% of a Ascophyllum nodosum extract and a flos mori extract: 40-60% of the formulated composition. Further preferred weight percentages are 50%:50% of the formulated composition. Biochemical assay detection shows that the composition has synergistically enhanced activity of inhibiting protein glycosylation, and the composition has very low cytotoxicity. The invention also discloses the use of the seaweed-derived composition as an anti-glycation ingredient for the manufacture of cosmetic products, such as creams.
Description
Technical Field
The invention relates to an anti-saccharification composition of seaweed source, a preparation method thereof and application of the composition in making beauty products, and belongs to the field of cosmetics.
Background
Brownlee in 1984 reported the presence of advanced glycation end products (AGEs) in vivo. AGEs refer to a complex class of glycosylation products produced by biological macromolecules (nucleic acids, proteins, and lipids) through non-enzymatic catalytic mechanisms. Non-enzymatically catalyzed glycosylation reactions primarily refer to a series of chemical reactions that occur between the terminal free carbonyl groups of reducing monosaccharide molecules and the free amino groups in nucleic acid, protein and lipid macromolecules (FIG. 1). Studies have found that AGEs products in vivo can be divided into three major categories: non-crosslinked non-fluorescent product, and non-crosslinked fluorescent product. More than 20 AGEs products have been identified from human blood and tissues.
AGEs are potentially toxic molecules that threaten human health. For example, glycosylation of protein molecules in vivo may result in changes in the secondary structure of the protein molecule, thereby affecting the function of the protein, until it leads to cell damage. In addition, collagen is an important tissue protein in the skin, and as the age and high-sugar eating habit increase, collagen is gradually saccharified, and the skin becomes hard and black, and finally skin aging is caused and the beauty is affected. Therefore, if the glycosylation level of biological macromolecules in the body can be effectively inhibited, the biological macromolecules can be helpful for improving some disease states, delaying aging and keeping the young state of skin. It has been found that partial natural products with antioxidant activity are effective in inhibiting AGEs formation, i.e. Anti-glycation activity, while the cytotoxicity of these natural products is relatively small. The literature reports that natural products capable of inhibiting AGEs formation include polyphenols, polysaccharides, terpenoids, vitamins, alkaloids and polypeptides, which inhibit AGEs formation by different mechanisms.
Natural products are an important source of anti-glycation active products. The early screening of the project group can obtain part of seaweed extract and plant extract with obvious anti-saccharification activity, and different natural products can resist the formation of AGEs through different mechanisms. For the combination of different extracts, the combination of different AGEs inhibition mechanisms aims to find seaweed extract compositions with synergistic anti-glycation activity.
Algae are algae growing in the sea, and research finds that algae have many medicinal values, such as antiviral, antitumor, heart protection, etc. Seaweed is also used as an important cosmetic ingredient for making various cosmetic products. The seaweed beauty product has small irritation and high safety, and is popular with consumers. Ascophyllum nodosum (ASCOPHYLLUM NODOSUM) is a brown algae grown on seaside rock. The Ascophyllum nodosum contains abundant algal polysaccharides, mannitol, phenols, alginate, brown algae polyphenols, laminarin, fucoidan, cytokinin, gibberellin, etc., especially brown algae polyphenols have antiviral and antitumor effects. Flos Magnoliae (MAGNOLIA BIONDII), flos Magnoliae, is a deciduous shrub or small arbor of the genus Wang Chun of the family Magnoliaceae, and its medicinal parts are mainly flower buds and bark. The spring flower is mild in property and pungent in taste, and has the effects of dispelling wind-cold, dredging lung meridian, regulating resuscitation, easing pain and the like. The flos Magnoliae mainly contains magnolol, magnolol toxin, marjoram alkali, magnolol, E-p-hydroxy ethyl cinnamate, flavonoids of flos Magnoliae, and magnolol. No report on the pharmacodynamic activity of single components or compositions of the extract of Ascophyllum nodosum and the extract of Wangchun in inhibiting the formation of AGEs is known so far.
Disclosure of Invention
The invention aims to provide a composition prepared by mixing two extracts, namely, a Ascophyllum nodosum (ASCOPHYLLUM NODOSUM) extract and a flos mori (MAGNOLIA BIONDII) extract, and a preparation method thereof.
The invention aims to solve the technical problem that the extract of Ascophyllum nodosum and the extract of flos verrucae rugosa have certain anti-saccharification activity. The mixture of the two has synergistically enhanced anti-glycation activity relative to the single ingredient. In addition, the Ascophyllum nodosum extract, the Wangchun extract and the mixture of the two have very low cytotoxicity.
Yet another technical problem to be solved by the present invention is the use of the above composition for preparing seaweed extract as a cosmetic ingredient for preparing a cosmetic product, such as a face cream. The seaweed extract composition exhibits good anti-glycation activity, which contributes to improving the aging state of the skin.
In order to solve the technical problems of the invention, the invention adopts the following technical scheme:
the first aspect of the invention relates to a composition prepared by mixing two extracts, namely, a Ascophyllum nodosum extract and a flos mori extract according to a certain proportion, and the preparation method comprises the following steps:
the composition is prepared by mixing the extract of Ascophyllum nodosum and the extract of flos Hemerocallis according to a certain weight ratio, wherein the content of the extract of Ascophyllum nodosum is similar to that of the extract of flos Hemerocallis, and the weight percentages of the extract of Ascophyllum nodosum and the extract of flos Hemerocallis are as follows: extract of telescoping flower = 40-60%:40-60%, and mixing evenly after weighing.
Further preferred compositions are prepared as follows: extract of Ascophyllum nodosum: extract of telescoping flower = 50%:50% of the total weight of the components are weighed and evenly mixed.
The second aspect of the present invention relates to the use of a composition of seaweed origin as described above for the preparation of an anti-glycation product; the present invention demonstrates that the composition has synergistically enhanced anti-glycation activity compared to the single extract by virtue of the effect of the seaweed extract composition on the glycosylation of albumin, the composition being suitable as anti-glycation ingredient for the preparation of corresponding cosmetic products.
In a third aspect the present invention relates to the use of a composition of seaweed origin as described above for the preparation of cosmetic products, such as creams, having anti-glycation activity.
Drawings
Fig. 1: formation mechanism of advanced glycation end products (AGEs).
Fig. 2: anti-glycation activity studies of the different components. The four detection components are aminoguanidine, ascophyllum nodosum extract, flos Hemerocallis extract and preferred compositions of the extracts.
Fig. 3: anti-glycation activity IC of four components 50 . The four detection components are aminoguanidine, ascophyllum nodosum extract, flos Hemerocallis extract and preferred compositions of the extracts.
Detailed Description
The following examples and activity experiments are provided to further illustrate the invention, but are not intended to limit the scope of the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
Example 1: preparation method of seaweed-derived extract composition
The extract of Ascophyllum nodosum (ASCOPHYLLUM NODOSUM) is a brown yellow powder, readily soluble in water, available from the Sichuan Biotech Co. Flos Wallichii (MAGNOLIA BIONDII) extract, brown powder, is easily dissolved in water, and is purchased from Shaanxi New Tian Domain biotechnology Co. The preparation method of the composition comprises the following steps: the composition consists of a Ascophyllum nodosum extract and a flos verrucae vulgaris extract according to similar weight ratio, wherein the weight percentages of the Ascophyllum nodosum extract and the flos verruceae extract are as follows: extract of telescoping flower = 40-60%:40-60%, and mixing evenly after weighing.
Further, the preferred method of preparation of the composition is as follows: extract of Ascophyllum nodosum: extract of telescoping flower = 50%: weighing and uniformly mixing 50% by weight. In the specific operation, 5g of the Ascophyllum nodosum extract and the Wangchun extract are respectively weighed, mixed and stirred uniformly, and the extract composition of seaweed sources is obtained.
Example 2: anti-glycation activity of seaweed-derived extract composition
Experimental method: the inhibitory activity of Ascophyllum nodosum extract, wangchun extract and the preferred composition prepared in Experimental example 1 on AGEs formation was examined according to the study methods proposed by Vinson and Howard in 1996. Samples of 0.5mL at a concentration of 10,20,50,100,200 μg/mL were added to 0.1M PBS buffer containing 0.5mL 20mg/mL BSA, 0.5mL 0.5M glucose and 1.0mL 1% sodium azide, ph=7.4. Incubating at 37 deg.C for 7 days, and measuring with fluorescence spectrometerPerkin-Elmer, mass., USA) setting the detection conditions as E x ＝330nm,E m Fluorescence Intensity (FI) of AGEs formation was measured =410 nm. No inhibitor was added to the control group. The anti-glycation reference compounds were compared using aminoguanidine.
The inhibitory activity on AGEs formation was calculated by the following formula:
inhibitory Activity (%) = [1- (FI sample-FI sample blank)/(FI control-FI control blank) ]. Times.100%
Calculation of IC based on inhibition rates of different concentration components 50 The calculations were performed using the software GraphPad prism 8.0.
The results are as follows：
TABLE 1 anti-glycation Activity Studies of different Components
The experimental results are shown in table 1 and fig. 2. The extract of Ascophyllum nodosum or extract of flos Catharanthi rosei has certain anti-glycation activity, but is superior to aminoguanidine as positive compoundThe anti-glycation activity of (2) is still weak. For example, at 200. Mu.g/mL, the anti-glycation activities of Ascophyllum nodosum extract and Wangchun extract were 62% and 65%, respectively. The positive compound aminoguanidine had an anti-sugar inhibitory activity of 83% (similar to the data reported in the literature), but the extract of Ascophyllum nodosum and the extract of Wangchun flower were in the proportions of 50%: the preferred composition obtained by mixing 50% by weight has a significantly improved anti-glycation inhibiting activity. As shown in FIG. 3, IC for inhibiting AGEs formation was calculated using GraphPadPrsm 8.0 for the four components 50 58.74 mug/mL-aminoguanidine, 95.23 mug/mL-Ascophyllum nodosum extract, 83.34 mug/mL-flos Homophilae extract, 39.55 mug/mL-extract composition, respectively.
Example 3: synergistic effect of anti-glycation activity of seaweed-derived extract composition was confirmed
The experimental method comprises the following steps:the synergy index is judged by adopting a gold positive average q value method, and the q value is obtained by the following formula:
q＝P A+B /(P A +P B -P A ×P B ). P in the formula A 、P B And P A+B Treatment rates were set A, B and two combination groups, respectively.
q < 1 indicates antagonism after the two extracts are combined; q > 1, indicating synergy after the two extracts are combined, and q=1, indicating additive effect after the two extracts are combined.
According to the above-mentioned synergy index calculation method, we respectively measure single doses of Ascophyllum nodosum extract, flos Wallichii extract, and 50% of the two by weight percent: the preferred combination of 50% mixing is shown in Table 2 for specific concentrations. The inhibition activity of AGEs formation was examined in the same manner as in example 2.
The results are as follows：
TABLE 2 anti-glycation Activity Studies of two Components
The results of the measurement are shown in Table 2. At the three selected concentrations, the preferred compositions exhibit synergistic anti-glycation activity of both extracts, with a significant enhancement in anti-glycation activity. In the early stage of the project, we screened some traditional Chinese medicine extracts with anti-saccharification activity, and screened the composition with obvious enhancement effect by combining two by two. We speculate that since different extracts are rich in different anti-glycation natural product components, such as polyphenols or polysaccharides. If the two extracts adopt different anti-glycation inhibition mechanisms, the combination of the two extracts has mutual enhancement effect, and finally, the synergistic anti-glycation activity is achieved. Compositions, particularly preferred compositions, having synergistic significantly enhanced anti-glycation effects as compared to single extracts may be used as anti-glycation ingredients.
Example 4: cytotoxicity of seaweed-derived extract composition
The experimental method comprises the following steps:the cytotoxicity of the compounds was detected using the CCK-8 kit. Specifically, hepG2 cells, MCF-7 cells and A549 cells were inoculated into 96-well plates, respectively, and the cells were cultured overnight at about 5000 cells/200. Mu.L of the culture medium per well. Test compounds were added to each well at different concentrations and incubation was continued for 48 hours. And adding 10 mu L of CCK-8 reagent into each hole, uniformly mixing, continuously culturing for 1-4 hours, observing that the color of the culture solution changes obviously, detecting by using an enzyme-labeled instrument, and measuring the light absorption value of 450 nm. Paclitaxel was used as a positive control.
The results were as follows:
the results are shown in Table 3, and cell experiments show that the preferred compositions of Ascophyllum nodosum extract, wangchun extract and both have no significant cytotoxicity. This is relevant to the fact that they are derived from plant extracts. In combination with example 2 and example 3, the compositions of both are particularly preferred compositions suitable for use as anti-glycation ingredients in the preparation of cosmetic products.
TABLE 3 cytotoxicity of different fractions on mammalian cells
Example 5: cosmetic composition prepared from seaweed extract for preparing anti-saccharification facial cream
An anti-saccharification face cream comprises the following components in parts by weight:
the cosmetic ingredients appearing herein are all INCI (International Nomenclature of Cosmetic Ingredients), the name specified by the international cosmetic raw material nomenclature.
An oil phase: 3.0 parts of mineral oil, 3.0 parts of squalane, 2.0 parts of caprylic/capric triglyceride, 0.4 part of polyoxyethylene cetylstearyl diether, 4.0 parts of polydimethylsiloxane, and 4.0 parts of glycerol stearic acid/PEG-100 stearic acid;
aqueous phase:10.0 parts of an anti-glycation composition (preferred composition in example 1)3.0 parts of glycerin, 5.0 parts of propylene glycol, 0.1 part of allantoin, 0.15 part of carbomer, 65.03 parts of deionized water, 0.02 part of essence, 0.15 part of methylparaben and 0.15 part of propylparaben.
The preparation method comprises the following steps:according to the above formulation, the individual components were weighed, with each mass part being 1g. Mixing the oil phase components, stirring and heating to 80 ℃; mixing the water phase components (except essence), stirring and heating to 80deg.C; slowly adding the oil phase into the water phase, stirring while adding, keeping the temperature of the water phase constant at 80 ℃, and continuously stirring for 5 minutes; cooling to 45deg.C, adding essence, stirring, cooling to 25deg.C, and packaging.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (5)
1. A seaweed-derived composition having anti-glycation activity, characterized in that it comprises the following components in percentage by weight: 50% of Ascophyllum nodosum extract and 50% of flos hedyotis Dodecandri extract, wherein the composition has synergistic activity of inhibiting formation of advanced glycosylation end products, the Ascophyllum nodosum extract is purchased from Seira New Biotechnology Co., ltd, and the flos hedyotis Dodecandri extract is purchased from Shaanxi New Tian Biotechnology Co., ltd.
2. A method of preparing a seaweed-derived composition as claimed in claim 1, characterized in that it comprises the steps of: according to the weight percentage of claim 1, the extract of Ascophyllum nodosum and the extract of Wangchun are respectively weighed, and the two powders are evenly mixed, thus obtaining the seaweed-derived composition.
3. Use of the seaweed source composition of claim 1 for the preparation of a cosmetic product.
4. Use according to claim 3, characterized in that: the cosmetic product is selected from a cream, a toner, an emulsion or a mask.
5. An anti-glycation facial cream, characterized in that: the face cream contains the seaweed source composition of claim 1, and the formula and the weight parts of the face cream are as follows:
an oil phase: 3.0 parts of mineral oil, 3.0 parts of squalane, 2.0 parts of caprylic/capric triglyceride, 0.4 part of polyoxyethylene cetylstearyl diether, 4.0 parts of polydimethylsiloxane, and 4.0 parts of glycerol stearic acid/PEG-100 stearic acid;
aqueous phase: the seaweed-derived composition of claim 1, wherein the seaweed-derived composition comprises 10.0 parts of glycerol 3.0 parts, propylene glycol 5.0 parts, allantoin 0.1 parts, carbomer 0.15 parts, deionized water 65.03 parts, perfume 0.02 parts, methylparaben 0.15 parts, propylparaben 0.15 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111356423.3A CN113876640B (en) | 2021-11-16 | 2021-11-16 | Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111356423.3A CN113876640B (en) | 2021-11-16 | 2021-11-16 | Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113876640A CN113876640A (en) | 2022-01-04 |
| CN113876640B true CN113876640B (en) | 2023-10-31 |
Family
ID=79017745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111356423.3A Active CN113876640B (en) | 2021-11-16 | 2021-11-16 | Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113876640B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105377232A (en) * | 2013-04-12 | 2016-03-02 | 圣地亚哥大学 | Antioxidant extract from brown macroalgae and method for obtaining same |
| CN106176379A (en) * | 2016-08-09 | 2016-12-07 | 思拓科（上海）生物科技股份有限公司 | A kind of cosmetics, its preparation method and application |
| CN108210421A (en) * | 2018-03-26 | 2018-06-29 | 广东盛美化妆品有限公司 | A kind of whitening mask liquid of the extract containing Magnolia binodii and preparation method thereof |
| CN108392446A (en) * | 2018-04-16 | 2018-08-14 | 广州赛莱拉干细胞科技股份有限公司 | Skin care compositions based on yellow tang extract and its application |
| CN110101727A (en) * | 2019-06-21 | 2019-08-09 | 福建农林大学 | A kind of hypoglycemic yellow tang composite micro-capsule and preparation method thereof |
| KR20190137327A (en) * | 2018-06-01 | 2019-12-11 | 애경산업(주) | Skin external application composition for anti-aging |
| CN110623885A (en) * | 2019-10-28 | 2019-12-31 | 北京皓尔生物科技有限公司 | Anti-glycosylation yellow-dispelling and anti-aging composition and preparation method and application thereof |
| CN111700830A (en) * | 2020-06-29 | 2020-09-25 | 广州睿森生物科技有限公司 | Composition and application thereof in preparation of anti-glycosylation cosmetics |
| CN112494359A (en) * | 2020-12-15 | 2021-03-16 | 广州市尚梓化工科技有限公司 | Preparation method of seaweed oligosaccharide and application of seaweed oligosaccharide in anti-aging cosmetics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101795732B (en) * | 2007-04-19 | 2014-08-20 | 玫琳凯有限公司 | Magnolia extract containing compositions |
-
2021
- 2021-11-16 CN CN202111356423.3A patent/CN113876640B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105377232A (en) * | 2013-04-12 | 2016-03-02 | 圣地亚哥大学 | Antioxidant extract from brown macroalgae and method for obtaining same |
| CN106176379A (en) * | 2016-08-09 | 2016-12-07 | 思拓科（上海）生物科技股份有限公司 | A kind of cosmetics, its preparation method and application |
| CN108210421A (en) * | 2018-03-26 | 2018-06-29 | 广东盛美化妆品有限公司 | A kind of whitening mask liquid of the extract containing Magnolia binodii and preparation method thereof |
| CN108392446A (en) * | 2018-04-16 | 2018-08-14 | 广州赛莱拉干细胞科技股份有限公司 | Skin care compositions based on yellow tang extract and its application |
| KR20190137327A (en) * | 2018-06-01 | 2019-12-11 | 애경산업(주) | Skin external application composition for anti-aging |
| CN110101727A (en) * | 2019-06-21 | 2019-08-09 | 福建农林大学 | A kind of hypoglycemic yellow tang composite micro-capsule and preparation method thereof |
| CN110623885A (en) * | 2019-10-28 | 2019-12-31 | 北京皓尔生物科技有限公司 | Anti-glycosylation yellow-dispelling and anti-aging composition and preparation method and application thereof |
| CN111700830A (en) * | 2020-06-29 | 2020-09-25 | 广州睿森生物科技有限公司 | Composition and application thereof in preparation of anti-glycosylation cosmetics |
| CN112494359A (en) * | 2020-12-15 | 2021-03-16 | 广州市尚梓化工科技有限公司 | Preparation method of seaweed oligosaccharide and application of seaweed oligosaccharide in anti-aging cosmetics |
Non-Patent Citations (2)
| Title |
|---|
| 冯峥 等.《药妆品与美容实践》.河南科学技术出版社,2020,第137页. * |
| 王建新.《化妆品植物原料大全》.中国纺织出版社,2012,第379-380页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113876640A (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
| CN112493480A (en) | Antioxidant composition and application thereof | |
| Abdullah et al. | Characteristics of Turbinaria conoides and Padina minor as raw materials for healthy seaweed salt | |
| CN113876640B (en) | Anti-saccharification seaweed source composition, preparation method thereof and application thereof in cosmetic product | |
| KR101987421B1 (en) | Cosmetic composition for improving antioxidation and skin wrinkle comprising bertholletia excelsa seed oil, plukenetia volubilis seed oil, mangifera indica extract and fragaria chiloensis extract | |
| CN114948813B (en) | Anti-saccharification and anti-aging natural product composition, preparation method thereof and application thereof in oral cosmetic product | |
| EP2878342A1 (en) | Method for extraction of peat active substances and use of their combination in skin regenerating cosmetic formulations | |
| Toah et al. | In vitro oocysticidal sporulation inhibition of Eimeria tenella and antioxidant efficacy of ethanolic and aqueous extracts of Conyza aegyptiaca | |
| CN116370323A (en) | Whitening composition, skin care product and whitening liquid | |
| CN113876668B (en) | Anti-saccharification plant source composition, preparation method thereof and application thereof in cosmetic product | |
| CN113876669B (en) | Anti-saccharification traditional Chinese medicine composition, preparation method thereof and application thereof in cosmetic product | |
| KR101425902B1 (en) | Cosmetic composition for whitening of the skin comprising hydroxamic acid derivatives | |
| KR20200031288A (en) | Whitening, anti-wrinkle and anti-oxidant cosmetic composition comprising the mixed extract of Gloiopeltis tenax, Dulse and Sea spaghetti as an active ingredient and preparation method of the same | |
| Ghanwat et al. | Formulation and Evaluation of Herbal Soap | |
| Baruah et al. | Phytochemical study of some selected medicinal plants and its ethnobotanical importance to the indigenous communities of Assam | |
| TWI687237B (en) | Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin | |
| Thomas-Oates et al. | Cell protective antioxidants from the root bark of Lannea velutina A. Rich., a Malian medicinal plant | |
| CN112891278A (en) | Whitening composition, preparation method and application | |
| JP5450918B2 (en) | Topical skin preparation | |
| JP6562469B2 (en) | Hair pigment enhancer | |
| JP2007210965A (en) | Tyrosinase activity inhibitor, manufacturing method and use thereof | |
| IswaryaVelu et al. | Comparison of antioxidant activity and total phenolic content of Amaranthus tristis and Celosia argentea var spicata | |
| JP2004083484A (en) | Skin external preparation | |
| KR20150075514A (en) | Antiinflamatory Composition for Comprising Algae Extract Fucoxanthin | |
| Alzomor et al. | Extraction and formulation of rosemary as anti-wrinkle cream and gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |